Latest Regulatory Milestones News

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Blackstone Minerals is set to merge with IDM International, combining expertise and local presence to advance exploration of the world-class Mankayan copper-gold porphyry project in the Philippines.

Pure Hydrogen has handed over Australia’s first hydrogen fuel cell rear loader garbage truck to Solo Resource Recovery, marking a milestone in sustainable waste management and clean energy adoption.

Midway Limited’s shares have been suspended from trading following Federal Court approval of its acquisition by River Capital’s RCM BidCo Pty Ltd, marking a pivotal moment for the timber producer.

Australian Rare Earths Limited (AR3) has obtained South Australian Government approval to expand its Overland Uranium Project, gaining rights over an additional ~1,000km² and greenlighting immediate drilling on high-potential targets.

Wellnex Life has secured Therapeutic Goods Administration approval for its Liquid Paracetamol plus Caffeine Soft Gel, marking its fourth market authorisation and opening new revenue avenues.

Viridis Mining and Minerals has raised A$3.5 million through a placement to fund critical development milestones for its Colossus Rare Earth Element project, following a major resource upgrade.

Althea Group Holdings Limited has had its trading suspension lifted following a Federal Court ruling related to cleansing notice lodgement failures, marking a key regulatory milestone for the pharmaceutical company.

Findi Limited has received Reserve Bank of India approval to acquire Tata Communications' White Label ATM business, Indicash, marking a pivotal step in its expansion across India's financial services landscape.

MC Mining Limited reported a 26% drop in coal production and sales in Q2 FY2025, while advancing development at its flagship Makhado steelmaking coal project. The company also secured merger clearance and extended loan repayment terms, signaling a complex operational and financial landscape.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.